128-13-2 with low price of Ursodiol 128-13-2

 

Ursodeoxycholic acid Basic information

Choleretic drugs Pharmacological effects Chenodeoxycholic acid Drug Interactions Side effects Precautions Determination of the content ursodeoxycholic acid and chenodeoxycholic acid in bear bile by TLCS methodChemical Properties Uses Production method

Product Name:	Ursodeoxycholic acid
Synonyms:	Adursal;Ursic acid;34784-46-7;rsodeoxycholic acid;Porcine deoxycholic acid;Chenodeoxycholic Acid Impurity 1;(3a,5b,7b)-3,7-Dihydroxycholan-24-oic acid;7BETA-HYDROXYLITHOCHOLIC ACID
CAS:	128-13-2
MF:	C24H40O4
MW:	392.57
EINECS:	204-879-3
Product Categories:	API;Herb extract;DEPACON;BPC;Bile Acids;Inhibitors;Biochemistry;Steroids;Intermediates & Fine Chemicals;Pharmaceuticals;API's
Mol File:	128-13-2.mol

Ursodeoxycholic acid Chemical Properties

Melting point	203-204 °C(lit.)
alpha	60 º (c=2, EtOH)
Boiling point	437.26°C (rough estimate)
density	0.9985 (rough estimate)
refractive index	60.5 ° (C=2, EtOH)
Fp	9℃
storage temp.	Refrigerator
solubility	ethanol: 50 mg/mL, clear
form	Solution
pka	pKa 5.04±0.04(H2O t = 25.0±0.1 I = 0.00)(Approximate)
color	Clear colorless
Water Solubility	practically insoluble
Merck	14,9889
InChIKey	RUDATBOHQWOJDD-UZVSRGJWSA-N
CAS DataBase Reference	128-13-2(CAS DataBase Reference)

 

 

As the manufacturer of UDCA, we can provide it with lower price and high quality. We have engaged in UDCA market  for 10 years. We have been constantly innovating in technology, in order to reduce the costs, so that maxmize profits for our customers. Medical raw materials for hepatobiliary diseased. Adding bile acid to secrete bile acid and changing bile composition, reducing cholesterol and cholesterol lipid in bile is beneficial to the gradual dissolution of cholesterol in gallstones.

Pharmacological effects

Ursodeoxycholic acid, namely 3α, 7 β-dihydroxy bile acid, is the 7β-hydroxy epimer of chenodeoxycholic acid. Because of this small structural difference, the product is hydrophilic. It can reduce the activity of the rate-limiting enzyme in cholesterol synthesis in the liver--β-hydroxyl-β-methylglutaryl coenzyme A (HMG-CoA) reductase, thus inhibiting the cholesterol synthesis. It also forms a stable liquid crystalline suspension with cholesterol, and thus unsaturated the bile cholesterol, thereby promoting the separation and dissolution of cholesterol stone. This product can also inhibit the intestinal absorption of cholesterol. Ursodeoxycholic acid can also antagonize the cytotoxic effects of endogenous hydrophobic bile acids, protecting the liver cell membrane. By reducing the overexpression of the main membrane tissue compatibility antigen MHC-1, it can inhibit the production of interleukin-2,4, tumor necrosis factor and interferon α; and increasing the body's levels of interleukin-10,12; It also directly binds to the glucocorticoid receptor, playing a role in immune regulation. In addition, Ursodeoxycholic acid can also inhibit apoptosis, inhibit inflammation, scavenge free radical and have antioxidant effects. After oral administration, it is absorbed through non-ionic passive diffusion in the jejunum, and through active transport in the ileum. The effect of first-pass is large, 50% to 75% of the orally administrated dose is uptake by liver. It is mainly distributed in the liver, intestines and blood plasma, and has a 96% to 99% plasma protein binding rate. Ursodeoxycholic acid concentration in the bile exhibit dose-dependent increase; upon a dose of 20~30mg/(kg ? d), its concentration in bile is over 60%, reaching the best therapeutic effect. It binds to glycine, taurine in the liver, and is metabolized by intestinal. A small part of metabolite product is excreted from by urine, mostly by the fecal excretion. Biological half-life of oral administration is 3.5 to 5.8 days.

The above information is edited by the Chemicalbook of Dai Xiongfeng.